Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.85 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.78 |
| ▸ | CA1 | P00915 | 4/20 | 0.69 |
| ▸ | CA2 | P00918 | 4/20 | 0.69 |
| ▸ | CA7 | P43166 | 4/20 | 0.69 |
| ▸ | CA9 | Q16790 | 4/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.62 |
| ▸ | CDK8 | P49336 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118026 | 0.92 | KDR (1.00) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL29364392 | 0.92 | KDR (1.00) | KDRTRPV1CA1CA2CA7 | |
| Cloflucarban SCHEMBL27537485 | 0.89 | KDR (0.88) | KDRTRPV1CA1CA2CA7 | |
| Cloflucarban SCHEMBL119821 | 0.89 | KDR (0.88) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL16884950 | 0.88 | KDR (0.85) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL18615348 | 0.88 | KDR (0.85) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL11005015 | 0.88 | KDR (0.85) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL9084296 | 0.88 | KDR (0.85) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL4548158 | 0.88 | KDR (0.90) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL26697308 | 0.88 | KDR (0.74) | KDRTRPV1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | disclosed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | disclosed |
| CN-108530455-B | Urea substituted aromatic ring connecting dioxane and quinazoline compound or medicinal salt or hydrate and application as tyrosine kinase inhibitor | 北京赛特明强医药科技有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
| CN-108586330-A | A kind of preparation method and applications of tumor | 日照市普达医药科技有限公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-108530455-A | Aromatic ring Lian dioxanes simultaneously quinazoline compounds or pharmaceutical salts or hydrate and the application as tyrosine kinase inhibitor of urea substitution | 北京赛特明强医药科技有限公司 | 2018-09-14 | — | — | CN | disclosed |
| EP-3330254-A2 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2018-06-06 | — | — | EP | disclosed |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-2220042-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2010-08-25 | — | — | EP | disclosed |
| EP-2195286-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | Cipla Limited (IN) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009063054-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2009-05-22 | — | — | WO | disclosed |
| EP-2060565-A1 | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases | 4SC AG (DE) | 2009-05-20 | — | — | EP | disclosed |
| WO-2009054004-A2 | PROCESS FOR THE PREPARATION OF SORAFENIB | NATCO PHARMA LIMITED (IN) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009054004-A2 | PROCESS FOR THE PREPARATION OF SORAFENIB | NATCO PHARMA LIMITED (IN) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009034308-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034308-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BRAF, RAF1, ARAF | KDR 5/4885TRPV1 2906/4885CA1 2792/4885 |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BRAF, RAF1, ARAF | KDR 5/4885TRPV1 2906/4885CA1 2792/4885 |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | BRAF, RAF1, ARAF | KDR 272/4885TRPV1 2007/4885CA1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.